-
1.发明授权Composition and use of Lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases 有权副干酪乳杆菌菌株GMNL-133在治疗特应性皮炎或其他过敏性疾病中的组成和用途公开(公告)号：US08753624B2
公开(公告)日：2014-06-17
申请号：US13273228
申请日：2011-10-14
Applicant: Ying-Chen Lu , Feng-Ching Hsieh
Inventor： Ying-Chen Lu , Feng-Ching Hsieh
IPC: A01N63/00
CPC classification number: A61K35/747 , A23L33/135 , A23V2002/00 , A23Y2220/63 , A61K35/744 , A61K35/745 , C12N1/20 , C12R1/225 , A61K2300/00 , A23V2200/304 , A23V2200/3204
Abstract: An isolated Lactobacillus paracasei strain GMNL-133 is disclosed, which was deposited in the China Center for Type Culture Collection (CCTCC) under the accession number of CCTCC M 2011331 is disclosed. The isolated Lactobacillus paracasei strain GMNL-133 is used for preparing a composition for use in the treatment of atopic dermatitis or other allergic diseases in an effective amount. And a composition for use in the treatment of atopic dermatitis or other allergic diseases comprises an effective amount of the Lactobacillus paracasei strain GMNL-133 is also disclosed.
Abstract translation: 公开了一种孤立的副干酪乳杆菌菌株GMNL-133，该菌株以CCTCC M 2011331的保藏号存于中国型号培养物保藏中心（CCTCC）。 分离的副干酪乳杆菌菌株GMNL-133用于制备用于治疗特应性皮炎或其他有效量的过敏性疾病的组合物。 并且用于治疗特应性皮炎或其它过敏性疾病的组合物还包括有效量的副干酪乳杆菌菌株GMNL-133。
-
Patent Agency Ranking
2.发明授权Lactobacillus isolates having anti-inflammatory activities and uses of the same 有权具有抗炎活性的乳酸杆菌分离物及其用途公开(公告)号：US07901926B2
公开(公告)日：2011-03-08
申请号：US12340081
申请日：2008-12-19
Applicant: Tu-Wen Yu , Jun-Sheng Li , Feng-Ching Hsieh , Ching-Pei Chen , Tsuei-Yin Huang , Ying-Chen Lu
Inventor： Tu-Wen Yu , Jun-Sheng Li , Feng-Ching Hsieh , Ching-Pei Chen , Tsuei-Yin Huang , Ying-Chen Lu
CPC classification number: C12R1/225 , A23L33/135 , A23V2002/00 , A23Y2220/77 , A61K35/747 , C12N1/20 , Y10S435/853 , A23V2200/3204
Abstract: Disclosed herein are two Lactobacillus isolates having anti-inflammatory activities and beneficial probiotic properties, i.e., Lactobacillus sakei GMNL-76 and Lactobacillus reuteri GMNL-89, which were deposited in the Biosource Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (FIRDI) under accession numbers BCRC 910355 and BCRC 910340 and in the China Center for Type Culture Collection (CCTCC) under accession numbers CCTCC M 207153 and CCTCC M 207154, respectively. The two Lactobacillus isolates and their sub-cultured offspring can be used in the preparation of a variety of food products, and in the manufacture of pharmaceutical compositions for treating and/or alleviating diseases associated with inflammation, such as rheumatoid arthritis.
Abstract translation: 本文公开了两种具有抗炎活性和有益益生菌特性的分离乳杆菌的乳酸杆菌GMNL-76和赖氨酸乳杆菌GMNL-89，其保藏在食品工业研究与开发的生物源收集和研究中心（BCRC）中 研究所（FIRDI）分别以登记号BCRC 910355和BCRC 910340以及中国类型培养物保藏中心（CCTCC），登录号为CCTCC M 207153和CCTCC M 207154。 两种乳酸杆菌分离物及其亚培养的后代可用于制备各种食品，以及用于制备用于治疗和/或减轻与炎症相关的疾病如类风湿性关节炎的药物组合物。
-
3.发明申请COMPOSITION AND USE OF LACTOBACILLUS PARACASEI STRAIN GMNL-133 IN TREATING ATOPIC DERMATITIS OR OTHER ALLERGIC DISEASES 有权Lactobacillus paracasei菌株GMNL-133在治疗原发性或其他过敏性疾病中的组成和用途公开(公告)号：US20130095086A1
公开(公告)日：2013-04-18
申请号：US13273228
申请日：2011-10-14
Applicant: Ying-Chen LU , Feng-Ching HSIEH
Inventor： Ying-Chen LU , Feng-Ching HSIEH
CPC classification number: A61K35/747 , A23L33/135 , A23V2002/00 , A23Y2220/63 , A61K35/744 , A61K35/745 , C12N1/20 , C12R1/225 , A61K2300/00 , A23V2200/304 , A23V2200/3204
Abstract: An isolated Lactobacillus paracasei strain GMNL-133 is disclosed, which was deposited in the China Center for Type Culture Collection (CCTCC) under the accession number of CCTCC M 2011331 is disclosed. The isolated Lactobacillus paracasei strain GMNL-133 is used for preparing a composition for use in the treatment of atopic dermatitis or other allergic diseases in an effective amount. And a composition for use in the treatment of atopic dermatitis or other allergic diseases comprises an effective amount of the Lactobacillus paracasei strain GMNL-133 is also disclosed.
Abstract translation: 公开了一种孤立的副干酪乳杆菌菌株GMNL-133，该菌株以CCTCC M 2011331的保藏号存于中国型号培养物保藏中心（CCTCC）。 分离的副干酪乳杆菌菌株GMNL-133用于制备用于治疗特应性皮炎或其他有效量的过敏性疾病的组合物。 并且用于治疗特应性皮炎或其它过敏性疾病的组合物还包括有效量的副干酪乳杆菌菌株GMNL-133。
-
4.发明申请COMPOSITION AND USE OF PROBIOTIC STRAIN GM-263 (ADR-1) IN TREATING RENAL FIBROSIS IN DIABETES 审中-公开生物应变GM-263（ADR-1）在糖尿病治疗肾脏纤维化中的组成和用途公开(公告)号：US20120183504A1
公开(公告)日：2012-07-19
申请号：US13006432
申请日：2011-01-14
Applicant: Ying-Chen LU , Jau-Shyang HUANG , Feng-Ching HSIEH , Yi-Cheng LI , Chia-Lin LEE
Inventor： Ying-Chen LU , Jau-Shyang HUANG , Feng-Ching HSIEH , Yi-Cheng LI , Chia-Lin LEE
CPC classification number: A61K35/747 , A61K35/745 , A61K2300/00
Abstract: A use of probiotic strain GM-263 (ADR-1) in treating renal fibrosis in diabetes is disclosed. The probiotic strain such as Lactobacillus renteri strain GM-263 (ADR-1) (accession No. CCTCC M 209263) is utilized to produce a composition for treating renal fibrosis in diabetes in an effective dose, thereby reducing the concentration of glycated hemoglobin and blood sugar and keeping body weight and kidney weight within normal range, as well as specifically inhibiting phosphorylation of JAK2/STAT1 signal transduction pathway and renal fibrosis-related protein expression.
Abstract translation: 公开了益生菌菌株GM-263（ADR-1）在治疗糖尿病肾纤维化中的应用。 益生菌菌株如转基因乳杆菌菌株GM-263（ADR-1）（登录号CCTCC M 209263）用于产生有效剂量治疗糖尿病肾纤维化的组合物，从而降低糖化血红蛋白和血液的浓度 糖和保持体重和肾脏重量在正常范围内，以及特异性抑制JAK2 / STAT1信号转导通路和肾纤维化相关蛋白表达的磷酸化。
-
5.发明申请USE OF PROBIOTIC STRAIN GM-080 IN TREATING CARDIAC INFLAMMATION AND APOPTOSIS 审中-公开使用生物应变GM-080治疗心脏炎症和病变公开(公告)号：US20120052047A1
公开(公告)日：2012-03-01
申请号：US12947829
申请日：2010-11-17
Applicant: Ying-Chen LU , Feng-Ching HSIEH , Cheng-Chih TSAI , Chih-Yang HUANG , Hsueh-Fang WANG , Chien-Yu TSENG
Inventor： Ying-Chen LU , Feng-Ching HSIEH , Cheng-Chih TSAI , Chih-Yang HUANG , Hsueh-Fang WANG , Chien-Yu TSENG
CPC classification number: A61K35/747 , A23L33/135 , A23V2002/00 , A23Y2220/63 , A61K2035/115 , C12N1/20 , C12R1/225 , A23V2200/3204 , A23V2200/326
Abstract: A use of probiotic strain GM-080 in treating cardiac inflammation and apoptosis is disclosed. The probiotic strain GM-080 such as Lactobacillus paracasei strain GM-080 (accession No. CCTCC M 204012) is utilized to produce a composition for treating cardiac inflammation and apoptosis in an effective dose.
Abstract translation: 公开了益生菌菌株GM-080在治疗心脏炎症和细胞凋亡中的应用。 利用益生菌菌株GM-080，例如副干酪乳杆菌菌株GM-080（登录号CCTCC M 204012）产生有效剂量治疗心脏炎症和细胞凋亡的组合物。
-
6.发明申请Lactobacillus Isolates Having Anti-Inflammatory Activities and Uses of the Same 有权具有抗炎活性的乳杆菌分离物及其用途公开(公告)号：US20090274672A1
公开(公告)日：2009-11-05
申请号：US12340081
申请日：2008-12-19
Applicant: Tu-Wen Yu , Jun-Sheng Li , Feng-Ching Hsieh , Ching-Pei Chen , Tsuei-Yin Huang , Ying-Chen Lu
Inventor： Tu-Wen Yu , Jun-Sheng Li , Feng-Ching Hsieh , Ching-Pei Chen , Tsuei-Yin Huang , Ying-Chen Lu
CPC classification number: C12R1/225 , A23L33/135 , A23V2002/00 , A23Y2220/77 , A61K35/747 , C12N1/20 , Y10S435/853 , A23V2200/3204
Abstract: Disclosed herein are two Lactobacillus isolates having anti-inflammatory activities and beneficial probiotic properties, i.e., Lactobacillus sakei GMNL-76 and Lactobacillus reuteri GMNL-89, which were deposited in the Biosource Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (FIRDI) under accession numbers BCRC 910355 and BCRC 910340 and in the China Center for Type Culture Collection (CCTCC) under accession numbers CCTCC M 207153 and CCTCC M 207154, respectively. The two Lactobacillus isolates and their sub-cultured offspring can be used in the preparation of a variety of food products, and in the manufacture of pharmaceutical compositions for treating and/or alleviating diseases associated with inflammation, such as rheumatoid arthritis.
Abstract translation: 本文公开了两种具有抗炎活性和有益益生菌特性的分离乳杆菌的乳酸杆菌GMNL-76和赖氨酸乳杆菌GMNL-89，其保藏在食品工业研究与开发的生物源收集和研究中心（BCRC）中 研究所（FIRDI）分别以登记号BCRC 910355和BCRC 910340以及中国类型培养物保藏中心（CCTCC），登录号为CCTCC M 207153和CCTCC M 207154。 两种乳酸杆菌分离物及其亚培养的后代可用于制备各种食品，以及用于制备用于治疗和/或减轻与炎症相关的疾病如类风湿性关节炎的药物组合物。
-
-
-
-
-
Search Results
6
records
(took 0.014 seconds)
